Company Encyclopedia
View More
name
Tempus AI
TEM.US
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies.
770.89 B
TEM.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking21/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-72.61%E
    • Profit Margin-18.45%D
    • Gross Margin62.82%A
  • Growth ScoreA
    • Revenue YoY72.58%A
    • Net Profit YoY74.54%A
    • Total Assets YoY134.78%A
    • Net Assets YoY845.18%A
  • Cash ScoreC
    • Cash Flow Margin-542.12%E
    • OCF YoY72.58%A
  • Operating ScoreB
    • Turnover0.68B
  • Debt ScoreE
    • Gearing Ratio77.74%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Rhumbline Advisers Raises Stock Holdings in Tempus AI, Inc. $TEM

    Rhumbline Advisers significantly increased its holdings in Tempus AI by 3,633.2% in Q2. Other institutional investors also boosted their stakes. Insiders sold shares, with EVP Andrew Polovin and CFO James Rogers reducing their positions. Analysts have mixed ratings, with a consensus target price of $81.17. Tempus AI's stock opened at $74.91, with a 52-week range of $31.36 to $104.32.

    Market Beat·
    US
    TEM
    +1.90%
    Market Beat·
    US
    TEM
    +1.90%

    Tempus AI COO Ryan Fukushima Reports Disposal of Common Shares

    Ryan Fukushima, COO of Tempus AI Inc., reported the disposal of common shares of the company. The filing is available via EDGAR, the SEC's system. This AI-generated news is for informational purposes only and not financial advice.

    Reuters·
    US
    TEM
    +1.90%
    Reuters·
    US
    TEM
    +1.90%

    Tempus AI Director Jennifer Doudna Reports Sale of Common Shares

    Jennifer A. Doudna, Director at Tempus AI Inc., reported the sale of common shares of the company. The information was published via EDGAR by Tempus AI Inc. on December 03, 2025. This brief was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    TEM
    +1.90%
    Reuters·
    US
    TEM
    +1.90%

    Morgan Stanley upgrades Tempus AI to overweight

    Morgan Stanley upgraded Tempus AI to an "overweight" rating, raising the price target to $85. Analysts highlighted Tempus' rapid growth in hereditary cancer risk testing, following its acquisition of Ambry Genetics. They also noted potential in Tempus' data and services unit. Despite Tempus' unprofitability since its 2024 IPO, it has gained favor among analysts, with 10 out of 17 giving it a buy rating. Tempus' share price has more than doubled this year.

    Sherwoodnews·
    US
    TEM
    +1.90%
    Sherwoodnews·
    US
    TEM
    +1.90%

    Tempus AI (TEM): Assessing Valuation Following Analyst Optimism on Growth Drivers and Precision Medicine Collaboration

    Tempus AI's valuation is assessed following analyst optimism on growth drivers like Ambry acquisition and precision medicine collaboration. Share price surged 127% YTD, with fair value at $91, indicating undervaluation. Risks include high price-to-sales ratio and competition. Analysis is not financial advice.

    Simplywall·
    US
    TEM
    +1.90%
    Simplywall·
    US
    TEM
    +1.90%
    Posts
    View More

    $Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals Inc.（RXRX）Weekly Report (2025.11.22-11.29) The extent of your achievements can largely be seen from how much pain you can endure...

    Breaking 🚨:

    Back on 1/21, Nancy pelosi filed a new buy of Tempus AI

    If you Autopiloted her $Tempus AI(TEM.US) buy from the day she filed you'd be up 110%

    She's really taking "public servant" to a whole ...
    • 0
    • 1

    This is why Pelosi is the GOAT 🐐

    Back on 1/20 she filed a new buy of Tempus AI

    She was the first politician to have ever bought $Tempus AI(TEM.US)

    $Tempus AI(TEM.US) is now up 110% since her trade becam......
    • 0
    • 1

    $Tempus AI(TEM.US)

    TEM's stock price suddenly dropped by 15%, which must have made many people panic and think about selling immediately. However, I believe this might actually be a good buying opportu...

    $Tempus AI(TEM.US)I deleted it after stop loss before, but this time I bought it again after stop loss, breaking through a psychological barrier. But now I'm hesitating whether to chase it again or no...

    • 0
    • 1
    © 2025 Longbridge｜Disclaimer